MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurheartj/ehad028

Медицинская библиотека · European heart journal · 2023

Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration.

Nollet Edgar E, Duursma Inez, Rozenbaum Anastasiya, Eggelbusch Moritz, Wüst Rob C I, Schoonvelde Stephan A C, Michels Michelle, Jansen Mark, van der Wel Nicole N, Bedi Kenneth C, Margulies Kenneth B, Nirschl Jeff, Kuster Diederik W D, van der Velden Jolanda

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

AIMS: Genetic hypertrophic cardiomyopathy (HCM) is caused by mutations in sarcomere protein-encoding genes (i.e. genotype-positive HCM). In an increasing number of patients, HCM occurs in the absence of a mutation (i.e. genotype-negative HCM). Mitochondrial dysfunction is thought to be a key driver of pathological remodelling in HCM. Reports of mitochondrial respiratory function and specific disease-modifying treatment options in patients with HCM are scarce.

METHODS AND

RESULTS

Respirometry was performed on septal myectomy tissue from patients with HCM (n = 59) to evaluate oxidative phosphorylation and fatty acid oxidation. Mitochondrial dysfunction was most notably reflected by impaired NADH-linked respiration. In genotype-negative patients, but not genotype-positive patients, NADH-linked respiration was markedly depressed in patients with an indexed septal thickness ≥10 compared with <10. Mitochondrial dysfunction was not explained by reduced abundance or fragmentation of mitochondria, as evaluated by transmission electron microscopy. Rather, improper organization of mitochondria relative to myofibrils (expressed as a percentage of disorganized mitochondria) was strongly associated with mitochondrial dysfunction. Pre-incubation with the cardiolipin-stabilizing drug elamipretide and raising mitochondrial NAD+ levels both boosted NADH-linked respiration.

CONCLUSION

Mitochondrial dysfunction is explained by cardiomyocyte architecture disruption and is linked to septal hypertrophy in genotype-negative HCM. Despite severe myocardial remodelling mitochondria were responsive to treatments aimed at restoring respiratory function, eliciting the mitochondria as a drug target to prevent and ameliorate cardiac disease in HCM. Mitochondria-targeting therapy may particularly benefit genotype-negative patients with HCM, given the tight link between mitochondrial impairment and septal thickening in this subpopulation.

Для цитирования: Nollet Edgar E, Duursma Inez, Rozenbaum Anastasiya, Eggelbusch Moritz, Wüst Rob C I, Schoonvelde Stephan A C, Michels Michelle, Jansen Mark, van der Wel Nicole N, Bedi Kenneth C, Margulies Kenneth B, Nirschl Jeff, Kuster Diederik W D, van der Velden Jolanda. Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration.. European heart journal. 2023. DOI: 10.1093/eurheartj/ehad028.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.